The American journal of tropical medicine and hygiene · 2022
The Importance of Partnership in the Rollout of Triple-Drug Therapy to Eliminate Lymphatic Filariasis in the Pacific.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rainima-Qaniuci Merelesita, Lepaitai Hansell Blanche, Bhagirov Rasul, Padmasiri Eswara, Naseri Take, Thomsen Robert, Won Kimberly Y, Brant Tara A, Dodd Emily, Nua Motusa Tuileama, Utu Fara, Tufa Aifili, Chutaro Emi, Camacho Janet, Suiaunoa-Scanlan Lynette, Thean Li Jun, Mani Jyotishna, Hardy Myra, Samuela Josaia, Romani Lucia, Kaldor John, Steer Andrew C, Faktaufon Daniel, Bechu Vinaisi, Naqio Flora, Sosene Vine, Sekihara Makoto, Otaki Junko, Buhagiar Tamara S, Yajima Aya
Аннотация
We discuss the experience of some Pacific island countries in introducing the new WHO-recommended treatment protocol for lymphatic filariasis-a triple-drug therapy composed of ivermectin, diethylcarbamazine, and albendazole. The successful rollout of the new treatment protocol was dependent on strong partnerships among these countries' ministries of health, WHO, and other stakeholders. Effective communication among these partners allowed for lessons learned to cross borders and have a positive impact on the experiences of other countries. We also describe various challenges confronted during this process and the ways these countries overcame them.